RNN News 0.98 Rexahn Pharmaceuticals (RNN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Rexahn Pharmaceuticals (RNN) 0.98 $RNN

Hot Stock: Rexahn Pharmaceuticals, Shares Drop 17.4% (RNN)
Comtex SmarTrend(R) - Tue Apr 15, 10:11AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 17.4% to $0.83 on 1.7x average daily volume. Rexahn Pharmaceuticals has traded 11.4 million shares thus far today, vs. average volume of 6.9 million shares per day. The stock has underperformed the Dow (-17.4% to the Dow's -0.1%) and underperformed the S&P 500 (-17.4% to the S&P's -0.1%) during today's trading.

Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick" announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.

Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting
Business Wire - Wed Apr 02, 8:00AM CDT
--RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity

Active Equities Updates -- Research on Valero Energy, UTi Worldwide, SLM Corp., and Rexahn Pharma
PR Newswire - Tue Apr 01, 8:00AM CDT
The trading session on Monday, March 31, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,457.66, up 0.82% and the NASDAQ Composite closed at 4,198.99, up 1.04%. The S&P 500 finished the session 0.79% higher at 1,872.34. The gains were broad based as nine out of ten sectors finished higher. During the session, gains in the Health Care, Materials, and Utilities sectors positively impacted the broader market. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Valero Energy Corp. (NYSE: VLO), UTi Worldwide Inc. (NASDAQ: UTIW), SLM Corp. (NASDAQ: SLM) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on VLO, UTIW, SLM and RNN can be downloaded upon signing up at:

Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
Business Wire - Mon Mar 24, 7:00AM CDT
--Archexin(R) Phase IIa clinical trial initiated in metastatic renal cell carcinoma

3 Stocks Under $10 Making Big Moves
at The Street - Wed Mar 19, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
Business Wire - Mon Mar 17, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director, Business Development, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Wednesday, March 19, 2014. Dr. Sharma will also serve on an expert panel titled "Strategies for small molecules and biologicals drug development." The conference will take place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY.

This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the  SPDR S&P Biotech Index  up  59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Phase I Data on Rexahn's Supinoxin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:30PM CDT
Initial data from phase I study on Rexahn's Supinoxin showed that the drug was well tolerated in cancer patients with solid tumors.

Why Rexahn Pharmaceuticals Inc. Jumped Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rexahn Pharmaceuticals , a clinical-stage...

Rexahn Pharmaceuticals Up 11.1%, Shares Break Through Resistance (RNN)
Comtex SmarTrend(R) - Tue Mar 11, 11:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 11.1% to $1.38 on 1.0x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 11.0 million shares, vs. average volume of 10.6 million shares per day. The stock has outperformed the Dow (10.7% to the Dow's -0.3%) and outperformed the S&P 500 (10.7% to the S&P's -0.3%) during today's trading.

Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:

Rexahn Announces Initial Results from Phase I Trial of Supinoxin(TM) (RX-5902) for Solid Cancer Tumors
Business Wire - Tue Mar 11, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of Supinoxin(TM) (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference
Business Wire - Tue Mar 04, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company's Chief Executive Officer and Ted Jeong, Chief Financial Officer, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 2:00 p.m. Pacific Time. The conference takes place at The Ritz-Carlton in Dana Point, California. A webcast of the presentation will be available on www.rexahn.com.

Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors
Business Wire - Mon Mar 03, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the company's Board of Directors.

Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.

4 Biotech Stocks Under $10 Moving Higher
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.

5 Stocks Under $10 Set to Soar
at The Street - Thu Feb 06, 2:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Axis Auto Finance's Strategic Asset Sale to Fionic Canada Ltd.

Updated Category News Views 269

Axis Auto Finance Announces Significant Asset Sale Axis Auto Finance Inc. is on the cusp of a major transformation. The Company, recognized for providing innovative auto financing solutions, has entered into an asset purchase agreement with Fionic Canada Ltd. and its affiliates for the sale of its auto finance business. This agreement marks a pivotal moment for Axis as it...

Continue Reading
Investors Anticipate Earnings Report for Brixmor Property Group

Updated Category News Views 144

Anticipating Earnings from Brixmor Property Group Brixmor Property Group (NYSE: BRX) is set to reveal its quarterly earnings, igniting curiosity and hope among investors. With expectations high, many are eager to see if the company can surpass estimates and provide encouraging guidance for the upcoming quarter. Expected Earnings Per Share Analysts are predicting an...

Continue Reading
Growing Demand for Tympanostomy Products: Market Insights

Updated Category News Views 115

Overview of the Tympanostomy Products Market The global tympanostomy products market is anticipated to flourish, driven significantly by the increasing prevalence of ear infections and heightened awareness regarding ear health. This surge reflects a broader trend in modern healthcare where innovative solutions are being sought to tackle persistent health issues. Market...

Continue Reading
Enhancing Global Climate Data with WIS 2.0 Test Infrastructure

Updated Category News Views 161

Revolutionizing Environmental Data Access Synoptic Data, a leading Public Benefit Corporation, has embarked on an exciting journey to enhance global environmental data with the development of the WIS 2.0 Test Infrastructure. This initiative arises from the pressing need for dependable and real-time environmental observations, particularly for regions that have...

Continue Reading
DTF Tax-Free Income Fund Outlines New Dividend Payments

Updated Category News Views 75

DTF Tax-Free Income 2028 Term Fund Inc. Readies for Dividend Payments The Board of Directors of DTF Tax-Free Income 2028 Term Fund Inc. (NYSE: DTF), a closed-end fund, has declared upcoming dividend payments for its common stock. This decision underscores the Fund's dedication to providing its investors with steady income through carefully curated portfolios of tax-exempt...

Continue Reading